1P-LSD blotter papers, as identified by the photographer.
DickStuert · CC BY-SA 4.0
About 1P-LSD
1P-LSD, or 1-propanoyl-LSD, is a lysergamide related to LSD. Chemical similarity does not make a research product an approved medicine.
Also searched as: 1p lsd · 1-propanoyl-LSD · 1-propionyl-LSD
Buy 1P-LSD: pricing & legal access
1P-LSD online: availability & product information
Do not infer legality from a seller’s “research only” wording or from absence of a familiar name on a list. Applicable analogue, possession and import rules require jurisdiction-specific verification. DrugRX has no verified consumer pharmacy price.
Pricing status: No live price feed or verified quote. DrugRX does not sell or dispense products.
Sources: DEA — Controlled-substance analogue guidance and statutory references
1P-LSD information
Relationship to LSD
A pharmacokinetic report involving two volunteers found evidence supporting conversion of 1P-LSD to LSD in humans. This very small study helps explain metabolism but cannot establish broad clinical safety or therapeutic benefit.
Effects and uncertainty
The report examined subjective effects and blood and urine measurements. It does not supply reliable population-level rates for rare adverse effects or long-term outcomes. LSD-like pharmacology is a reason for caution, not proof of identical risk.
Dosage evidence
A two-person pharmacokinetic report cannot define a safe general-use dose. DrugRX does not convert laboratory findings into instructions for using blotters, liquids or powders.
Interactions
A validated consumer interaction profile is not established by the cited study. Because LSD formation was observed, clinicians should know about both the reported product and other psychoactive medicines.
Identity and naming
The 1P prefix identifies a propanoyl substitution on an LSD-related structure. It is not a brand code for ordinary LSD, and similarly named lysergamides should not be treated as spelling variants of one compound.
Evidence for conversion to LSD
In the cited two-volunteer report, analysis of biological samples supported metabolism of 1P-LSD to LSD. The conclusion concerns the material and study conditions investigated, not every product described online as 1P-LSD.
Why sample size matters
A study with two volunteers can help investigate metabolism, but cannot reliably estimate rare adverse events, interactions across many medicines, or outcomes in people with different medical histories. Absence of a reported problem in that sample is not a population safety estimate.
Interpreting research-chemical claims
A research-only label describes a seller’s stated context. It does not itself demonstrate chemical analysis, clinical approval or a legal exemption. Chemistry evidence and authorization to supply a consumer product are separate matters.
Sources: DEA — Controlled-substance analogue guidance and statutory references · FDA — Psychedelic drugs: clinical investigations
Sources and editorial notes
Prepared by DrugRX using the references linked below. Sources were consulted on 2026-10-31. This page has not been independently reviewed by a clinician. Research findings, medication approval and legal permission are separate questions.
- 1P-LSD pharmacokinetics in two volunteers (2020)
- DEA — Controlled-substance analogue guidance and statutory references
- FDA — Psychedelic drugs: clinical investigations
Legal information is a dated U.S. reference. Product rules and local laws may change. Where the evidence does not establish a dose, interaction profile or price, the page states that limitation.